Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Context Therapeutics
Biotech
Context ends bispecific trial to extend runway deeper into 2027
Context stopped development of the bispecific T-cell engager CT-95, freeing up cash to extend its runway beyond readouts on two priority programs.
Nick Paul Taylor
Aug 6, 2026 5:55am
20-year Novo vet lands first CEO role—Chutes & Ladders
May 30, 2025 8:30am
Context builds bispecific bank with $133M biobucks deal
Sep 23, 2024 11:20am
Assembly, Context and Innate add to pile of dumped R&D prospects
Mar 23, 2023 8:00am
Context cuts excess fat to carry biotech into ‘24
Sep 28, 2022 11:00am
